Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP)

Coeptis Therapeutics Holdings, Inc. (COEP), a company operating in the biotechnology industry, is dedicated to the development of novel therapies for various diseases, including oncology, respiratory viral infections, and autoimmune diseases. Its primary business activities revolve around researching, developing, and commercializing innovative therapeutic solutions. Coeptis Therapeutics Holdings, Inc. conducts its operations primarily in the United States, although its partnerships and collaborations span across various regions.

The company's revenue is generated through the development and commercialization of its products. Coeptis Therapeutics Holdings, Inc.'s primary products include CD38-GEAR-NK, a natural killer (NK) cell therapy for the treatment of CD38+ cancers, and CD38-Diagnostic, an in vitro diagnostic tool aimed at identifying cancer patients who may be appropriate candidates for anti-CD38 monoclonal antibody therapy. CD38-GEAR-NK is an autologous, gene-edited, NK cell-based therapeutic designed to protect CD38+ NK cells from destruction by anti-CD38 monoclonal antibodies. CD38-Diagnostic, on the other hand, is an in vitro diagnostic tool that helps clinicians identify patients who may benefit from CD38-targeted therapies, thereby reducing the risk of treatment failure.

Coeptis Therapeutics Holdings, Inc. maintains a strong position within the biotechnology industry, primarily due to its robust pipeline of products and strategic partnerships. The company's main competitors include other biotechnology companies focused on oncology, respiratory viral infections, and autoimmune diseases. Coeptis Therapeutics Holdings, Inc.'s competitive advantages lie in its innovative product portfolio and strategic collaborations.

While the text does not provide specific names of customers, it does mention partnerships with Vy-Gen Bio, Inc. and the University of Pittsburgh. Vy-Gen Bio, Inc. is a biotechnology company developing novel therapies for various diseases, and Coeptis Therapeutics Holdings, Inc. has a co-development agreement with this company for CD38-GEAR-NK and CD38-Diagnostic. The University of Pittsburgh is a leading research institution, and Coeptis Therapeutics Holdings, Inc. has a sponsored research agreement with this institution for the development of SNAP-CAR.

As for the company's product brands, Coeptis Therapeutics Holdings, Inc.'s portfolio includes CD38-GEAR-NK, CD38-Diagnostic, SNAP-CAR, and CPT60621. SNAP-CAR is a universal therapeutic platform being developed to treat various types of cancer, while CPT60621 is a novel, ready-to-use, oral liquid version of an already approved drug for the treatment of Parkinson's disease. Coeptis Therapeutics Holdings, Inc. has a co-development agreement with Vici Health Sciences, LLC for CPT60621.